leadf
logo-loader
viewOpen Orphan PLC

Open Orphan announce £2.5m influenza challenge study contract

Open Orphan PLC's (LON:ORPH) Cathal Friel talks to Proactive London about the £2.5m contract to carry out an influenza human challenge study for an unnamed US biotechnology company won by their hVIVO arm.

Friel explains that they are not a 'one trick Covid pony' and since they it has been a number of years since they have done a Flu trial, he says there will be 'many more in the months ahead'.

The challenge study will take place at the company’s 24-bedroom quarantine clinic in east London in the second half of next year with completion due by the end of 2021.

Quick facts: Open Orphan PLC

Price: 24.7 GBX

AIM:ORPH
Market: AIM
Market Cap: £165.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE gains as hopes rise of UK and France solving port chaos

FTSE 100 edged higher as France and the UK said they were near to ending the freight ban which has led to hundreds of lorries queuing outside Dover. London’s blue-chip index added 13 to 6,429 in spite of rising concerns over the new strain of COVID-19.   Mixed news for the UK economy...

4 weeks, 2 days ago

2 min read